1
|
Naumann F, Kaanders J, Peeters W, Adema G, Sweep F, Bussink J, Span P. Radiotherapy induces an increase in serum antioxidant capacity reflecting tumor response. Clin Transl Radiat Oncol 2024; 45:100726. [PMID: 38292333 PMCID: PMC10825560 DOI: 10.1016/j.ctro.2024.100726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 11/22/2023] [Accepted: 01/10/2024] [Indexed: 02/01/2024] Open
Abstract
Background and purpose Radiotherapy (RT) is a mainstay component of treatment for patients with head and neck squamous cell carcinoma (HNSCC), but responses vary. As RT relies upon oxidative damage, antioxidant expression in response to RT-induced reactive oxygen species (ROS) could compromise treatment response. We aimed to examine local and systemic antioxidant responses to increased RT-induced ROS in relation to treatment success. Materials and methods Nuclear factor erythroid 2-related factor 2 (NRF2), the main antioxidant transcription factor, was immunofluorescently stained in FaDu cells and in tumor biopsies of patients with oral cavity/oropharynx HNSCC before and after five fractions of RT. Besides, total antioxidant capacity (TAC) was analyzed in HNSCC tumor cells in vitro and in serum of HNSCC patients before, during, and after RT. Results Data revealed an increase in NRF2 expression and TAC in head and neck cancer cells in vitro over the course of 5 daily fractions of 2 Gy. In accordance, also in patients' tumors NRF2 expression increased, which was associated with increased serum TAC during RT. Increasing serum TAC was related to impaired local tumor control. Conclusion Radiation induced NRF2 expression and upregulated TAC, which may compromise the effect of RT-induced ROS. Changes in serum TAC during RT could serve as a novel predictor of treatment outcome in HNSCC patients.Medical Ethics Review Committee (CMO) approval - CMO number: 2007/104.
Collapse
Affiliation(s)
- F.V. Naumann
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - J.H.A.M. Kaanders
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - W.J.M. Peeters
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - G.J. Adema
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - F.C.G.J. Sweep
- Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - J. Bussink
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - P.N. Span
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
2
|
Naumann FV, Sweep FCGJ, Adema GJ, Peeters WJM, Martens JWM, Bussink J, Span PN. Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer. Cancer Metab 2023; 11:3. [PMID: 36755288 PMCID: PMC9909892 DOI: 10.1186/s40170-023-00304-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 01/29/2023] [Indexed: 02/10/2023] Open
Abstract
BACKGROUND Recently, we reported that tamoxifen-resistant (TAM-R) breast cancer cells are cross-resistant to irradiation. Here, we investigated the mechanisms associated with tamoxifen-induced radioresistance, aiming to prevent or reverse resistance and improve breast cancer treatment. METHODS Wild-type ERα-positive MCF7 and ERα-negative MDA-MB-231 breast cancer cells and their TAM-R counterparts were analyzed for cellular metabolism using the Seahorse metabolic analyzer. Real-time ROS production, toxicity, and antioxidant capacity in response to H2O2, tamoxifen, and irradiation were determined. Tumor material from 28 breast cancer patients before and after short-term presurgical tamoxifen (ClinicalTrials.gov Identifier: NCT00738777, August 19, 2008) and cellular material was analyzed for NRF2 gene expression and immunohistochemistry. Re-sensitization of TAM-R cells to irradiation was established using pharmacological inhibition. RESULTS TAM-R cells exhibited decreased oxygen consumption and increased glycolysis, suggesting mitochondrial dysfunction. However, this did not explain radioresistance, as cells without mitochondria (Rho-0) were actually more radiosensitive. Real-time measurement of ROS after tamoxifen and H2O2 exposure indicated lower ROS levels and toxicity in TAM-R cells. Consistently, higher antioxidant levels were found in TAM-R cells, providing protection from irradiation-induced ROS. NRF2, a main activator of the antioxidant response, was increased in TAM-R cells and in tumor tissue of patients treated with short-term presurgical tamoxifen. NRF2 inhibition re-sensitized TAM-R cells to irradiation. CONCLUSION Mechanisms underlying tamoxifen-induced radioresistance are linked to cellular adaptations to persistently increased ROS levels, leading to cells with chronically upregulated antioxidant capacity and glycolysis. Pharmacological inhibition of antioxidant responses re-sensitizes breast cancer cells to irradiation.
Collapse
Affiliation(s)
- F. V. Naumann
- grid.10417.330000 0004 0444 9382Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, 6500 HB the Netherlands
| | - F. C. G. J. Sweep
- grid.10417.330000 0004 0444 9382Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - G. J. Adema
- grid.10417.330000 0004 0444 9382Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, 6500 HB the Netherlands
| | - W. J. M. Peeters
- grid.10417.330000 0004 0444 9382Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, 6500 HB the Netherlands
| | - J. W. M. Martens
- grid.5645.2000000040459992XDepartment of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - J. Bussink
- grid.10417.330000 0004 0444 9382Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, 6500 HB the Netherlands
| | - P. N. Span
- grid.10417.330000 0004 0444 9382Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, 6500 HB the Netherlands
| |
Collapse
|
3
|
Fernandes MG, Stam B, Wijsman R, Bussink J, Monshouwer R. Relationship between Cardiac Dose and Overall Survival after Radiotherapy in a Large Cohort of Patients with Locally Advanced NSCLC. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
4
|
Naumann F, Adema G, Sweep F, Bussink J, Span P. OC-0429 Tamoxifen induces metabolic adaptations leading to radioresistance in breast cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02565-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Boreel D, Span P, Peters H, Kip A, Boswinkel M, Adema G, Heskamp S, Bussink J. OC-0593 SPECT Imaging of CAIX and monitoring of hypoxia after OXPHOS inhibition in murine tumor models. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02615-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Pfaehler E, Zhovannik I, Wei L, Boellaard R, Dekker A, Monshouwer R, El Naqa I, Bussink J, Gillies R, Wee L, Traverso A. A systematic review and quality of reporting checklist for repeatability and reproducibility of radiomic features. Phys Imaging Radiat Oncol 2021; 20:69-75. [PMID: 34816024 PMCID: PMC8591412 DOI: 10.1016/j.phro.2021.10.007] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 10/28/2021] [Accepted: 10/29/2021] [Indexed: 12/12/2022] Open
Abstract
Main factors impacting feature stability: Image acquisition, reconstruction, tumor segmentation, and interpolation. Textural features are less robust than morphological or statistical features. A checklist is provided including items that should be reported in a radiomic study.
Purpose Although quantitative image biomarkers (radiomics) show promising value for cancer diagnosis, prognosis, and treatment assessment, these biomarkers still lack reproducibility. In this systematic review, we aimed to assess the progress in radiomics reproducibility and repeatability in the recent years. Methods and materials Four hundred fifty-one abstracts were retrieved according to the original PubMed search pattern with the publication dates ranging from 2017/05/01 to 2020/12/01. Each abstract including the keywords was independently screened by four observers. Forty-two full-text articles were selected for further analysis. Patient population data, radiomic feature classes, feature extraction software, image preprocessing, and reproducibility results were extracted from each article. To support the community with a standardized reporting strategy, we propose a specific reporting checklist to evaluate the feasibility to reproduce each study. Results Many studies continue to under-report essential reproducibility information: all but one clinical and all but two phantom studies missed to report at least one important item reporting image acquisition. The studies included in this review indicate that all radiomic features are sensitive to image acquisition, reconstruction, tumor segmentation, and interpolation. However, the amount of sensitivity is feature dependent, for instance, textural features were, in general, less robust than statistical features. Conclusions Radiomics repeatability, reproducibility, and reporting quality can substantially be improved regarding feature extraction software and settings, image preprocessing and acquisition, cutoff values for stable feature selection. Our proposed radiomics reporting checklist can serve to simplify and improve the reporting and, eventually, guarantee the possibility to fully replicate and validate radiomic studies.
Collapse
Affiliation(s)
- Elisabeth Pfaehler
- Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Ivan Zhovannik
- Department of Radiation Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.,Department of Radiation Oncology (MAASTRO), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Lise Wei
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
| | - Ronald Boellaard
- Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.,Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
| | - Andre Dekker
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - René Monshouwer
- Department of Radiation Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Issam El Naqa
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
| | - Jan Bussink
- Department of Radiation Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Robert Gillies
- Department of Radiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Leonard Wee
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Alberto Traverso
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| |
Collapse
|
7
|
Naumann F, Adema G, Sweep F, Bussink J, Span P. PH-0441 DNA- and mitochondrial damage may be involved in tamoxifen-induced radioresistance. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07332-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Bussink J. SP-0017 Application of metabolic imaging for the predication and assessment of treatment response. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08460-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Slager E, Wijsman R, Van Melle J, Hummel Y, Bussink J, Mohammed N, Willems T, Hoendermis E, Langendijk J, Muijs C, Van Luijk P. PD-0419: Thoracic radiotherapy decreases right ventricle function: first results of the CLARIFY study. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00441-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Fernandes M, Teuwen J, Wijsman R, Stam B, Moriakov N, Bussink J, Monshouwer R. PO-1747: Segmentation of the heart using a Residual Unet model. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01765-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Linthorst C, Wijsman R, Fernandes M, Barbara S, Teuwen J, Bosboom D, Monshouwer R, Bussink J. PO-0992: Pericardial effusion after radiotherapy for Non-Small Cell Lung Cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01009-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Van Lith S, Huizing F, Hoeben B, Doulkeridou S, Gotthardt M, Van Bergen en Henegouwen P, Heskamp S, Bussink J. OC-0204: Molecular imaging of the endogenous hypoxia related marker CA IX with 111In-labeled VHH B9. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00228-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Span PN, Bussink J. The Role of Hypoxia and the Immune System in Tumor Radioresistance. Cancers (Basel) 2019; 11:cancers11101555. [PMID: 31615071 PMCID: PMC6826392 DOI: 10.3390/cancers11101555] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 10/11/2019] [Accepted: 10/12/2019] [Indexed: 01/18/2023] Open
Affiliation(s)
- Paul N Span
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
| | - Jan Bussink
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| |
Collapse
|
14
|
|
15
|
Apolle R, Appold S, Bussink J, Faivre-Finn C, Khalifa J, Lievens Y, De Ruysscher D, Van Elmpt W, Troost E. EP-1367 Target volumes in adaptive treatment of NSCLC show large discrepancies among experts. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31787-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Zhovannik I, Shi Z, Dankers F, Deist T, Traverso A, Kalendralis P, Monshouwer R, Bussink J, Fijten R, Aerts H, Dekker A, Wee L. PO-0951 How to build accurate prediction models without sharing patient data across hospitals? Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31371-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Deist T, Dankers F, Ojha P, Marshall S, Janssen T, Faivre-Finn C, Masciocchi C, Valentini V, Wang J, Chen J, Zhang Z, Spezi E, Button M, Nuyttens J, Vernhout R, Van Soest J, Jochems A, Monshouwer R, Bussink J, Price G, Lambin P, Dekker A. OC-0544 Distributed learning on 20 000+ lung cancer patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30964-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Huizing F, Hoeben B, Boerman O, Heskamp S, Bussink J. OC-0267 Imaging the effect of Atovaquone on the hypoxia-related marker CAIX in head and neck cancer models. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30687-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Zhovannik I, Bussink J, Fijten R, Dekker A, Monshouwer R. EP-1903 Learning from scanners: radiomics correction modeling. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32323-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Göttgens EL, Ostheimer C, Span PN, Bussink J, Hammond EM. HPV, hypoxia and radiation response in head and neck cancer. Br J Radiol 2019; 92:20180047. [PMID: 29493265 PMCID: PMC6435089 DOI: 10.1259/bjr.20180047] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 02/26/2018] [Accepted: 02/26/2018] [Indexed: 12/21/2022] Open
Abstract
Over the last decades, the incidence of human papilloma virus (HPV) positive head and neck squamous-cell carcinoma (HNSCC) has significantly increased. Infection with high-risk HPV types drives tumourigenesis through expression of the oncoproteins E6 and E7. Currently, the primary treatment of HNSCC consists of radiotherapy, often combined with platinum-based chemotherapeutics. One of the common features of HNSCC is the occurrence of tumour hypoxia, which impairs the efficacy of radiotherapy and is a negative prognostic factor. Therefore, it is important to detect and quantify the severity of hypoxia, as well as develop strategies to specifically target hypoxic tumours. HPV-positive tumours are remarkably radiosensitive compared to HPV-negative tumours and consequently the HPV-positive patients have a better prognosis. This provides an opportunity to elucidate mechanisms of radiation sensitivity, which may reveal targets for improved therapy for HPV-negative head and neck cancers. In this review, we will discuss the differences between HPV-positive and HPV-negative head and neck tumours and methods of hypoxia detection and targeting in these disease types. Particular emphasis will be placed on the mechanisms by which HPV infection impacts radiosensitivity.
Collapse
Affiliation(s)
- Eva-Leonne Göttgens
- Department of Radiation Oncology, Radiotherapy & OncoImmunology laboratory, Radboud University Medical Center, Nijmegen, Netherlands
| | | | - Paul N Span
- Department of Radiation Oncology, Radiotherapy & OncoImmunology laboratory, Radboud University Medical Center, Nijmegen, Netherlands
| | - Jan Bussink
- Department of Radiation Oncology, Radiotherapy & OncoImmunology laboratory, Radboud University Medical Center, Nijmegen, Netherlands
| | - Ester M Hammond
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
| |
Collapse
|
21
|
Heskamp S, Verhoeff S, Wierstra P, Molkenboer-Kuenen J, Sandker G, Thordardottir S, Olive D, Bussink J, Boerman O, Dolstra H, Aarntzen E, Hobo W. PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Woliner-van der Weg W, Span PN, Braam PM, Bussink J. Imageable Biomarkers for Radiotherapy Response. Prog Tumor Res 2018; 44:11-24. [PMID: 38243419 DOI: 10.1159/000486985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2024]
Abstract
Ideally, each patient with a malignancy who is eligible for radiation therapy should receive the most tumoricidal form of this this treatment with the lowest possible risk of toxicity. To overcome radiotherapy resistance, some patients would benefit from a more aggressive approach. This could be treatment intensification, for example by acceleration of the treatment to prevent the negative effects of accelerated tumor cell proliferation, or by boosting certain areas to specifically address intrinsic radioresistance, or a combination of radiotherapy with, for example, a hypoxic cell sensitizer or chemotherapy to reduce the radiotherapy resistance caused by hypoxia. For some patients, one of these approaches can be beneficial but for others could lead to unacceptable side effects. Therefore, it is highly desirable to make the selection upfront. The use of imageable biomarkers could be the key to a more patient-tailored treatment. Different biomarkers for hypoxia and proliferation that could be valuable for radiotherapy are discussed here, including their mechanism, the imaging procedure, quantification, and the value of the results.
Collapse
|
23
|
Kusters M, Creemers I, Van Kollenburg P, Bouwmans L, Schinagl D, Bussink J. PO-1070: Automated volumetric modulated arc therapy treatment planning for stage III NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31380-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Huizing F, Hoeben B, Franssen G, Boerman O, Heskamp S, Bussink J. OC-0266: Quantitative assessment of CAIX expression with SPECT imaging in head and neck cancer xenografts. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30576-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Adema G, Den Brok M, Van den Bijgaart R, Wassink M, Hoogenboom M, Bussink J, Futterer J. SP-0014: In situ Cancer Vaccines: Tumor destruction and immune stimulation for local and systemic tumor control. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30458-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
26
|
Woliner-van der Weg W, Gelens N, Leijser-Kersten V, Braam P, Bussink J, Wendling M. EP-1634: Combined 4D and 3D cone beam CT protocol for lung SBRT for reliable and fast position verification. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)32069-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
27
|
Post A, Smid M, Nagelkerke A, Martens J, Bussink J, Sweep C, Span P. OC-0482: Interferon stimulated genes: a common pathway in tamoxifen- and radioresistance in breast cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30922-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Jochems A, Hoebers F, De Ruysscher D, Leijenaar R, Walsh F, O'Sullivan B, Bussink J, Monshouwer R, Leemans R, Lambin P. OC-0035: Characterization and validation of a radiomics signature for NSCLC and head and neck cancer patients. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30479-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Iversen A, Busk M, Bertelsen L, Laustsen C, Munch O, Nielsen T, Wittenborn T, Bussink J, Lok J, Stødkilde-Jørgensen H, Horsman M. PV-0369: The potential of hyperpolarized 13 C MRS to monitor the effect of vascular disrupting agents. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30811-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Hendriks L, Brouns A, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt J, Bootsma G, Belderbos J, De Ruysscher D, Van Den Heuvel M, Dingemans AM. P2.02-021 Extracranial Progression (ePD) after Chemoradiotherapy (CRT) for Stage III NSCLC: Does the Chemotherapy Regimen Matter? J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Hendriks LE, Brouns >AJ, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt J>A, Bootsma GP, Belderbos JS, De Ruysscher DK, Van den Heuvel MM, Dingemans AMC. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter? Lung Cancer 2016; 101:68-75. [DOI: 10.1016/j.lungcan.2016.09.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 09/08/2016] [Indexed: 12/25/2022]
|
32
|
Campos D, Peeters W, Nickel K, Burkel B, Bussink J, Kimple R, van der Kogel A, Eliceiri K, Kissick M. SU-G-TeP3-10: Radiation Induces Prompt Live-Cell Metabolic Fluxes. Med Phys 2016. [DOI: 10.1118/1.4957090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Meijer T, Vriens D, Looijen-Salamon M, Visser E, Geus-Oei LD, Bussink J. EP-1851: Quantitative assessment of glucose metabolic rate within NSCLC histologies using dynamic 18F-FDG PET. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33102-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
34
|
Post A, Nagelkerke A, Martens J, Bussink J, Sweep C, Span P. PO-0997: Interferon response genes in breast cancer resistance to endocrine treatment and radiotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32247-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Heijmen L, Ter Voert EGW, Punt CJA, Heerschap A, Oyen WJG, Bussink J, Sweep CGJ, Laverman P, Span PN, de Geus-Oei LF, Boerman OC, van Laarhoven HWM. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging 2015; 9:237-45. [PMID: 24700751 DOI: 10.1002/cmmi.1564] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Revised: 07/24/2013] [Accepted: 08/01/2013] [Indexed: 01/17/2023]
Abstract
The purpose of this study was to assess the effect of bevacizumab on vasculature and hypoxia in a colorectal tumor model. Nude mice with subcutaneous LS174T tumors were treated with bevacizumab or saline. To assess tumor properties, separate groups of mice were imaged using (18) F-Fluoromisonidazole (FMISO) and (18) F-Fluorodeoxyglucose (FDG) positron emission tomography or magnetic resonance imaging before and 2, 6 and 10 days after the start of treatment. Tumors were harvested after imaging to determine hypoxia and vascular density immunohistochemically. The T2 * time increased significantly less in the bevacizumab group. FMISO uptake increased more over time in the control group. Vessel density significantly decreased in the bevacizumab-treated group. The Carbonic anhydrase 9 (CAIX) and glucose uptake transporter 1 (GLUT1) fractions were higher in bevacizumab-treated tumors. However, the hypoxic fraction showed no significant difference. Bevacizumab led to shorter T2 * times and higher GLUT1 and CAIX expression, suggesting an increase in hypoxia and a higher glycolytic rate. This could be a mechanism of resistance to bevacizumab. The increase in hypoxia, however, could not be demonstrated by pimonidazole/FMISO, possibly because distribution of these tracers is hampered by bevacizumab-induced effects on vascular permeability and perfusion.
Collapse
Affiliation(s)
- L Heijmen
- Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Wijsman R, Dankers F, Troost E, Hoffmann A, Bussink J. PO-0661: Multivariable predictive modeling of acute esophageal toxicity after IMRT for advanced stage NSCLC. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40653-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Bussink J, Meijer T, Kaanders J, Span P. SP-0015: Tumour metabolism is a critical factor for molecular imaging. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40015-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
38
|
Dankers F, Wijsman R, Troost E, Bussink J, Hoffmann A. PO-0659: 2D dose-surface data does not improve predictive performance of NTCP model for esophageal toxicity. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40651-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Carvalho S, Leijenaar R, Troost E, Oberije C, Reymen B, Van Elmpt W, De Groot M, Bussink J, Meldolesi E, Valentini V, Dekker A, Lambin P. OC-0205: Prognostic value of pre-RT PET metrics of lymph nodes vs. primary tumor in NSCLC: which holds more information? Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40203-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
40
|
Troost EGC, Hoeben BAW, Laverman P, Bussink J, Oyen WJG. In response to "histopathologic validation of 3'-deoxy-3'-(18)F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice". Radiother Oncol 2014; 114:417-8. [PMID: 25511411 DOI: 10.1016/j.radonc.2014.11.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 11/17/2014] [Accepted: 11/20/2014] [Indexed: 11/27/2022]
Affiliation(s)
- Esther G C Troost
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Dr. Tanslaan 10, 6229 ET Maastricht, The Netherlands.
| | - Bianca A W Hoeben
- Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Peter Laverman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jan Bussink
- Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Wim J G Oyen
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
41
|
Usmanij EA, Bussink J, de Geus-Oei LF. In-treatment assessment of response in locally advanced NSCLC: paving the way for personalized medicine. Lung Cancer 2014; 86:374. [PMID: 25454200 DOI: 10.1016/j.lungcan.2014.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Accepted: 10/07/2014] [Indexed: 10/24/2022]
Affiliation(s)
- Edwin A Usmanij
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
| | - Jan Bussink
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Lioe-Fee de Geus-Oei
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| |
Collapse
|
42
|
Van Dijk L, Boerman O, Franssen G, Bussink J. HNSCC Tumor Xenograft Early Response Imaging After Irradiation With Cetuximab-F(ab’)2-SPECT and FDG-PET. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Hoeben BAW, Troost EGC, Bussink J, van Herpen CML, Oyen WJG, Kaanders JHAM. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients. Nuklearmedizin 2014; 53:60-6. [PMID: 24468965 DOI: 10.3413/nukmed-0625-13-09] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Accepted: 12/20/2013] [Indexed: 12/25/2022]
Abstract
AIM Early treatment response of head and neck cancer to radiotherapy concomitant with cetuximab was monitored by repetitive PET imaging with the proliferation tracer 18F-FLT. PATIENTS, METHODS Five head and neck cancer patients, treated with radiotherapy and concomitant cetuximab following cetuximab induction, received four 18F-FLT PET-CT scans before and during treatment. Changes in SUVpeak, SUVmean and CT- and PET-segmented gross tumour volumes were evaluated, as were correlations with immunohistochemical staining for Epidermal Growth Factor Receptor (EGFR) and Ki-67 (proliferation marker) in pre-treatment tumour biopsies. RESULTS 18F-FLT PET measured tumor responses to the induction dose of cetuximab varied from 43% SUVpeak decrease to 47% increase. After start of radiotherapy 18F-FLT PET parameters decreased significantly in all patients. No associations were found between PET parameters and EGFR or Ki-67 expression levels. CONCLUSION Proliferation of head and neck carcinomas shows a varying response to cetuximab induction, but consistently decreases after addition of radiotherapy.
Collapse
Affiliation(s)
- B A W Hoeben
- Bianca A.W. Hoeben, MD Radboud University Medical Center, Department of Radiation Oncology 874, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands, Tel. +31/24/361 45 15; Fax +31/24/361 07 92, E-mail:
| | | | | | | | | | | |
Collapse
|
44
|
Peeters S, Panth K, Lieuwes N, Bussink J, Van Dongen G, Dubois L, Lambin P. PO-0785: 89Zr-Cetuximab uptake in primary head and neck xenografts is independent of the expression of EGFR and perfusion. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30903-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
45
|
Span P, Nagelkerke A, Stegeman H, Bussink J. SP-0013: Tumour microenvironment, metastasis and radiation response. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30118-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Hoeben B, Starmans M, Leijenaar R, Dubois L, Van der Kogel A, Kaanders J, Boutros P, Bussink J. PO-0943: Systematic 18F-FDG PET and immunohistochemistry analysis for differentiation between head and neck tumors. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31061-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Kaanders J, Bussink J. SP-0527: Clinical interventions and biological stratification. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30633-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Stegeman H, Span PN, Cockx SC, Peters JPW, Rijken PFJW, van der Kogel AJ, Kaanders JHAM, Bussink J. EGFR-Inhibition Enhances Apoptosis in Irradiated Human Head and Neck Xenograft Tumors Independent of Effects on DNA Repair. Radiat Res 2013; 180:414-21. [DOI: 10.1667/rr3349.2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- H. Stegeman
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - P. N. Span
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - S. C. Cockx
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - J. P. W. Peters
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - P. F. J. W. Rijken
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - A. J. van der Kogel
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - J. H. A. M. Kaanders
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - J. Bussink
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| |
Collapse
|
49
|
Wijsman R, Kaanders JH, Oyen WJ, Bussink J. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging 2013; 57:244-256. [PMID: 24045621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Due to the amazing leap of technology in radiation oncology in the past few years, cancer treatment will become more individualized. Molecular imaging with PET contributed to this with its many tracers available, each of them visualizing a specific feature of a tumor and its microenvironment revealing the biological characteristics of cancer. Hypoxia is of interest as hypoxic tumor cells are associated with lower disease control because of an increased resistance to cytotoxic treatment. This is especially the case for radiotherapy. Treatment adaptations overcoming the negative effect of hypoxia have shown promising results. Several hypoxia tracers are available of which [18F]FMISO is studied most extensively, however other tracers are studied as well and the search for highly specific and reproducible PET tracers is still ongoing. Wide experience has been gained with the use of [18F]FDG PET as it is used on a routine basis for diagnosing and staging of cancer. Although not a specific marker for hypoxia, increased metabolic rate reflects increased proliferation and glycolysis indicating increased treatment resistance. Molecular imaging by means of PET creates an opportunity to provide personalized care, with optimal disease control, minimal toxicity and best cost-effectiveness.
Collapse
Affiliation(s)
- R Wijsman
- Department of Radiation Oncology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands -
| | | | | | | |
Collapse
|
50
|
Oyen WJG, Kaanders JHAM, Bussink J. Molecular imaging of hypoxia. Q J Nucl Med Mol Imaging 2013; 57:217-218. [PMID: 24045618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Affiliation(s)
- W J G Oyen
- Departments of Nuclear Medicine Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands -
| | | | | |
Collapse
|